Core Viewpoint - WuXi AppTec is expected to report significant revenue and profit growth, with a projected revenue increase of at least 45% and a net profit growth of over 38% by 2025, indicating strong business performance and market demand [1] Group 1: Financial Projections - The adjusted net profit is anticipated to grow by over 45%, and if excluding foreign exchange impacts, the growth could exceed 65% [1] - Revenue growth projections for 2025 to 2027 are 45.7%, 36.6%, and 31.7% respectively, while adjusted net profit growth is forecasted at 34.9%, 38.4%, and 32.9% [1] Group 2: Business Development - The company is set to achieve a record of 70 new comprehensive projects in 2025, representing a year-on-year growth of 32% [1] - The number of Process Performance Qualification (PPQ) projects is expected to surge by 125% to 18, highlighting strong commercial production potential [1] Group 3: Strategic Moves - To address increasing customer demand, the company announced a cash offer to acquire at least 60% of Easton Pharmaceuticals, which signifies a strategic enhancement of its production capabilities [1] Group 4: Analyst Rating - The target price for WuXi AppTec has been raised from HKD 74 to HKD 88, with a maintained "Buy" rating [1]
大行评级｜招银国际：上调药明合联目标价至88港元，维持“买入”评级